Literature DB >> 3887168

Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications.

J A Luetscher, F B Kraemer, D M Wilson, H C Schwartz, M Bryer-Ash.   

Abstract

Plasma renin exists in an active form or as an inactive zymogen that resembles a prorenin present in homogenates of human kidneys. We examined the relation of diabetes and its microvascular complications with the level of plasma inactive renin activated by dialysis to pH 3.3. Plasma inactive renin was measured in 235 diabetic patients and 90 nondiabetic controls. In the controls, the level of plasma inactive renin increased slightly with age but was never above 50 ng per milliliter per hour. In young diabetic patients studied within three years of the onset of diabetes the concentration of inactive renin was normal, and in some older diabetics without complications it remained within the age-adjusted normal range for many years. However, in patients with retinopathy or albuminuria, plasma inactive renin was above the normal range with few exceptions, reaching levels 50 to 200 per cent above the upper limits of normal in patients with nephropathy. The frequency of neuropathy was also significantly higher among patients with levels above the normal range. In 37 per cent of the diabetics followed during one to three years of conventional treatment, plasma inactive renin increased significantly, but in another group of diabetics under intensive treatment, the level rose in only 7 per cent and fell in 43 per cent. We conclude that there is a close association between a high level of plasma inactive renin and the presence of microvascular complications, and that the level of inactive renin can be modified by intensive treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887168     DOI: 10.1056/NEJM198505303122202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  69 in total

Review 1.  Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.

Authors:  Boutros El-Haddad; Scott Reule; Paul E Drawz
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

2.  Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

Authors:  Norman K Hollenberg; Naomi D L Fisher; Juerg Nussberger; George V Moukarbel; Ebrahim Barkoudah; A H Jan Danser
Journal:  J Hypertens       Date:  2011-12       Impact factor: 4.844

Review 3.  Processing and sorting of human prorenin.

Authors:  W A Hsueh; Y S Do; P H Wang
Journal:  Cell Biophys       Date:  1991 Oct-Dec

4.  Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay.

Authors:  H Yokota; F Mori; K Kai; T Nagaoka; N Izumi; A Takahashi; T Hikichi; A Yoshida; F Suzuki; Y Ishida
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

5.  Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat.

Authors:  J L Wilkinson-Berka; G Tan; K J Binger; L Sutton; K McMaster; D Deliyanti; G Perera; D J Campbell; A G Miller
Journal:  Diabetologia       Date:  2011-07-14       Impact factor: 10.122

6.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

7.  Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.

Authors:  Atsuhiro Ichihara; Matsuhiko Hayashi; Yuki Kaneshiro; Fumiaki Suzuki; Tsutomu Nakagawa; Yuko Tada; Yukako Koura; Akira Nishiyama; Hirokazu Okada; M Nasir Uddin; A H M Nurun Nabi; Yuichi Ishida; Tadashi Inagami; Takao Saruta
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM.

Authors:  S Mäkimattila; P Summanen; I Matinlauri; M Mäntysaari; A Schlenzka; M Aalto; K Irjala; H Yki-Järvinen
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

Review 9.  What is the role of renin inhibition in the treatment of diabetic kidney disease?

Authors:  Radko Komers
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

10.  Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system.

Authors:  J Wagner; A H Jan Danser; F H Derkx; T V de Jong; M Paul; J J Mullins; M A Schalekamp; D Ganten
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.